Myeloid/lymphoid Or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila), Translocated To, 3 (MLLT3) (C-Term) antibody Primary Antibody
- Binding Specificity
- Enzyme Immunoassay (EIA), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
- This antibody reacts to AF9 (MLLT3).
- Cross-Reactivity (Details)
- Species reactivity (expected):Mouse.
Species reactivity (tested):Human.
- Protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS
- This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of human MLLT3.
- Ig Fraction
- Alternative Name
- MLLT3 / AF9 (MLLT3 Antibody Abstract)
- The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t(9,11)(p22,q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified, BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed.Synonyms: ALL1 fused gene from chromosome 9 protein, Myeloid/lymphoid or mixed-lineage leukemia translocated to chromosome 3 protein, Protein AF-9, YEATS domain-containing protein 3, YEATS3
- Molecular Weight
- 63351 Da
- Gene ID
- 4300, 5874
- Application Notes
- ELISA: 1/1,000. Immunohistochemistry: 1/50 - 1/100. Western Blot: 1/100 - 1/500.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
- For Research Use only
- 0.25 mg/mL
- PBS, 0.09 % (W/V) Sodium Azide
- Sodium azide
- Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handling Advice
- Avoid repeated freezing and thawing.
- 4 °C/-20 °C
- Storage Comment
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
Ronquist, Sanchez, Dubois, Chioureas, Fonseca, Larsson, Ullén, Yachnin, Ronquist, Panaretakis: "Energy-requiring uptake of prostasomes and PC3 cell-derived exosomes into non-malignant and malignant cells." in: Journal of extracellular vesicles, Vol. 5, pp. 29877, 2016 (PubMed).
Ihle, Trautmann, Kuenstlinger, Huss, Heydt, Fassunke, Wardelmann, Bauer, Schildhaus, Buettner, Merkelbach-Bruse: "miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours." in: Molecular oncology, Vol. 9, Issue 7, pp. 1421-33, 2016 (PubMed).
Staab-Weijnitz, Fernandez, Knüppel, Maul, Heinzelmann, Juan-Guardela, Hennen, Preissler, Winter, Neurohr, Hatz, Lindner, Behr, Kaminski, Eickelberg: "FK506-Binding Protein 10, a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis." in: American journal of respiratory and critical care medicine, Vol. 192, Issue 4, pp. 455-67, 2015 (PubMed).
Vietri, Schink, Campsteijn, Wegner, Schultz, Christ, Thoresen, Brech, Raiborg, Stenmark: "Spastin and ESCRT-III coordinate mitotic spindle disassembly and nuclear envelope sealing." in: Nature, Vol. 522, Issue 7555, pp. 231-5, 2015 (PubMed).
Jankowska-Steifer, Madej, Niderla-Bielińska, Ruminski, Flaht-Zabost, Czarnowska, Gula, Radomska-Leśniewska, Ratajska: "Vasculogenic and hematopoietic cellular progenitors are scattered within the prenatal mouse heart." in: Histochemistry and cell biology, Vol. 143, Issue 2, pp. 153-69, 2015 (PubMed).
Wang, Jiang, Yang, Tang, Yang, Xu, Jiang, Liu: "Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma." in: Journal of molecular histology, Vol. 45, Issue 4, pp. 391-9, 2015 (PubMed).
Simkins, Crawford, Goudreau, Lookingland, Kaplan: "Enhanced humoral immunity in mice lacking CB1 and CB2 receptors (Cnr1-/-/Cnr2-/- mice) is not due to increased splenic noradrenergic neuronal activity." in: Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, Vol. 9, Issue 4, pp. 544-57, 2014 (PubMed).
Benedikt, Baltruschat, Scholz, Bursen, Arrey, Meyer, Varagnolo, Müller, Karas, Dingermann, Marschalek: "The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures." in: Leukemia, Vol. 25, Issue 1, pp. 135-44, 2011 (PubMed).
Takaki, Nakayama, Misawa, Nakagawa, Kuniyasu: "In vitro formation of enteric neural network structure in a gut-like organ differentiated from mouse embryonic stem cells." in: Stem cells (Dayton, Ohio), Vol. 24, Issue 6, pp. 1414-22, 2006 (PubMed).
Nasr, Mukhopadhyay, Zhang, Katzenstein: "Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining." in: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, Vol. 19, Issue 12, pp. 1631-7, 2006 (PubMed).
- Ronquist, Sanchez, Dubois, Chioureas, Fonseca, Larsson, Ullén, Yachnin, Ronquist, Panaretakis: "Energy-requiring uptake of prostasomes and PC3 cell-derived exosomes into non-malignant and malignant cells." in: Journal of extracellular vesicles, Vol. 5, pp. 29877, 2016 (PubMed).